Judson, IR, Calvert, AH, Gore, ME et al. (4 more authors) (1991) Phase II trial of trimelamol in refractory ovarian cancer. British Journal of Cancer, 63 (2). pp. 311-313. ISSN 0007-0920
Abstract
Trimelamol is an analogue of hexamethymelamine which exhibited activity against refractory ovarian cancer in phase I clinical trial. The dose limiting toxicity was leukopenia. In a phase II study, 42 patients with recurrent, or platinum-complex resistant, advanced ovarian cancer were treated using the dose schedule 800 mg m-2 i.v. daily for 3 days. There were one complete, three partial and five minor responses, objective response rate: 9.5%. The main toxicity observed was nausea and vomiting, myelosuppression was minor. The role of Trimelamol in the treatment of ovarian cancer remains to be defined, but its activity is limited in refractory disease.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 1991 Macmillan Press Ltd. Reproduced in accordance with the publisher's self-archiving policy. |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Clinical Cancer Research (Leeds) |
Depositing User: | Symplectic Publications |
Date Deposited: | 11 Jul 2016 09:13 |
Last Modified: | 11 Jul 2016 09:13 |
Published Version: | http://dx.doi.org/10.1038/bjc.1991.72 |
Status: | Published |
Publisher: | Cancer Research UK |
Identification Number: | 10.1038/bjc.1991.72 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:100581 |